AurKa Pharma was established as part of the TVM Life Science Ventures VII fund, to develop an
Aurora kinase A inhibitor called AK-01, an oncology compound that was originally discovered through a Lilly research and development program.
Eli Lilly and Company announced an agreement to acquire AurKa Pharma, a company established by TVM Capital Life Science to develop oncology compound AK-01, an
Aurora kinase A inhibitor that was originally discovered at Lilly.
AurKa Pharma is a company established by investment advisory and fund managers group TVM Capital Life Science to develop oncology compound AK-01, an
Aurora kinase A inhibitor that was originally discovered at Lilly.
It is known that Aurora kinase A and JAK2 pathway activation contributes to GVHD.
Aurora kinase A and JAK2 also significantly reduced GVHD in mice and allowed for the development of anti-cancer immune cells.
Betts et al., "Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining T reg and antitumor CTL function," Science Translational Medicine, 2017; 9 (372): eaai8269 DOI: 10.1126/scitranslmed.aai8269
Li, "Expre ssion of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis," Diagnostic Pathology, vol.
Caldas, "Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer," British Journal of Cancer, vol.
The researchers hypothesized that cotreatment with drugs that target both
Aurora kinase A and JAK2 could prevent GVHD better than either drug alone.